Mixed Lineage Kinase 2 (MLK2) and vascular homeostasis

混合谱系激酶 2 (MLK​​2) 和血管稳态

基本信息

  • 批准号:
    10664335
  • 负责人:
  • 金额:
    $ 17.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-06-01 至 2024-05-31
  • 项目状态:
    已结题

项目摘要

Project Summary Cardiovascular diseases are among the nation's leading causes of death and disability, with an estimated cost of more than $351 billion in the USA. Ischemia-induced angiogenesis plays an important role in the recovery of many vascular diseases. The endothelium plays an even more important role in vascular homeostasis as it regulates vascular tone, thrombosis, leukocyte trafficking, metabolism, and angiogenesis. Maintaining normal endothelial function requires balancing numerous physiological and pathophysiological stresses such as shear, hypoxia, and inflammation. Among the pathways mediating cellular stress, responses are the stress-activated members of the MAP kinase (MAPK) superfamily, which includes c-Jun N-terminal kinase (JNK) and p38 MAPK. JNK protein plays an important role in collateral artery formation during development. Recently, we have shown that neural JNK3 plays a significant role in blood flow recovery after hindlimb ischemia. In probing upstream components of the MAPK signaling cascade (MAP2K and MAP3K), we found that Mixed Lineage Kinase 2 (MLK2), a MAP3K and upstream regulator of MAPK, is expressed in endothelium and required for normal postnatal endothelial function. In fact, MLK2-deficient endothelial cells exhibit profound defects in angiogenesis as well as endothelial proliferation and migration. MLK2 also plays a significant role in VEGF signaling, which is required for proper endothelium function. RNA-seq data indicates that MLK2-deficient endothelial cells exhibit both basal and VEGF- induced upregulation of a broadly conserved microRNA, miR-146a, that has previously been linked to inflammation. Mimics of this miR-146a miRNA administered to wild-type endothelial cells recapitulate a broad spectrum of the MLK2-deficient phenotype, including defects in proliferation and VEGF signaling. Using these strategies, we should be able to develop a clear picture of how MLK2 influences endothelial function and vascular homeostasis. These data will be important as MLK inhibitors are being tested in the cancer field since very little data is understood regarding their cardiovascular consequences. Moreover, how Mlk2 influences the vasculature is a large gap in knowledge that we will address.
项目摘要 心血管疾病是全国死亡和残疾的主要原因之一,估计成本 美国超过3510亿美元。缺血诱导的血管生成在恢复中起重要作用 许多血管疾病。内皮在血管稳态中起着更为重要的作用 调节血管张力,血栓形成,白细胞运输,代谢和血管生成。保持正常 内皮功能需要平衡许多生理和病理生理应力,例如剪切, 缺氧和炎症。在介导细胞应激的途径中,反应是应力激活 MAP激酶(MAPK)超家族的成员,其中包括C-Jun N末端激酶(JNK)和P38 MAPK。 JNK蛋白在发育过程中在抵押动脉形成中起重要作用。最近,我们显示了 该神经JNK3在后肢缺血后在血流恢复中起着重要作用。在探测上游 MAPK信号级联(MAP2K和MAP3K)的组件,我们发现混合谱系激酶2 (MLK2)是MAPK的MAP3K和上游调节剂,在内皮中表达,正常需要 产后内皮功能。实际上,MLK2缺陷型内皮细胞在血管生成中表现出深刻的缺陷 以及内皮增殖和迁移。 MLK2在VEGF信号传导中也起着重要作用,即 适当的内皮功能所需。 RNA-seq数据表明MLK2缺陷型内皮细胞表现出 基础和VEGF诱导的广泛保守的microRNA Mir-146a的上调,以前具有 与炎症有关。对野生型内皮细胞施用的miR-146a miRNA的模仿 概括了MLK2缺陷的表型,包括增殖和VEGF缺陷 信号。使用这些策略,我们应该能够清楚地了解MLK2如何影响 内皮功能和血管稳态。这些数据将很重要,因为正在测试MLK抑制剂 在癌症领域,由于很少了解其心血管后果的数据。而且, MLK2如何影响脉管系统是我们将要解决的知识差距。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Shashi Kant其他文献

Shashi Kant的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Shashi Kant', 18)}}的其他基金

Reinforcing old warriors to treat Mycobacterium kansasii in shorter duration
强化老战士在更短的时间内治疗堪萨斯分枝杆菌
  • 批准号:
    10250999
  • 财政年份:
    2020
  • 资助金额:
    $ 17.31万
  • 项目类别:
PK/PD Optimized Cephalosporins Based Treatment Regimens for Children With MDR-TB
基于头孢菌素的 PK/PD 优化儿童耐多药结核病治疗方案
  • 批准号:
    10449269
  • 财政年份:
    2019
  • 资助金额:
    $ 17.31万
  • 项目类别:
PK/PD Optimized Cephalosporins Based Treatment Regimens for Children With MDR-TB
基于头孢菌素的 PK/PD 优化儿童耐多药结核病治疗方案
  • 批准号:
    10004700
  • 财政年份:
    2019
  • 资助金额:
    $ 17.31万
  • 项目类别:
PK/PD Optimized Cephalosporins Based Treatment Regimens for Children With MDR-TB
基于头孢菌素的 PK/PD 优化儿童耐多药结核病治疗方案
  • 批准号:
    10667456
  • 财政年份:
    2019
  • 资助金额:
    $ 17.31万
  • 项目类别:
PK/PD Optimized Cephalosporins Based Treatment Regimens for Children With MDR-TB
基于头孢菌素的 PK/PD 优化儿童耐多药结核病治疗方案
  • 批准号:
    10223394
  • 财政年份:
    2019
  • 资助金额:
    $ 17.31万
  • 项目类别:

相似国自然基金

高原低氧上调肝脏ANGPTL4基因的表达导致巨噬细胞M1/M2比例失衡从而促进肝脂肪化的机制研究
  • 批准号:
    82360333
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目
利用条件性基因敲除小鼠研究ANGPTL4在肝癌发生中的作用及机制
  • 批准号:
    81372192
  • 批准年份:
    2013
  • 资助金额:
    75.0 万元
  • 项目类别:
    面上项目
PPARγ和ANGPTL4基因表达在急性胰腺炎肺损伤发病机制中的作用及清胰汤的干预作用
  • 批准号:
    81173452
  • 批准年份:
    2011
  • 资助金额:
    65.0 万元
  • 项目类别:
    面上项目

相似海外基金

p27pTpT drives cancer-promoting inflammation and shapes the tumor microenvironment (TME) toward a more tumor-permissive state in vivo
p27pTpT 驱动促癌炎症,并将肿瘤微环境 (TME) 塑造为更适合体内肿瘤生长的状态
  • 批准号:
    10744370
  • 财政年份:
    2023
  • 资助金额:
    $ 17.31万
  • 项目类别:
Targeting the endothelial clock to treat perioperative myocardial ischemia
靶向内皮时钟治疗围手术期心肌缺血
  • 批准号:
    10705355
  • 财政年份:
    2022
  • 资助金额:
    $ 17.31万
  • 项目类别:
Elucidation of novel anti-angiogenic therapies for the prevention and treatment of neovascular glaucoma
阐明预防和治疗新生血管性青光眼的新型抗血管生成疗法
  • 批准号:
    10491662
  • 财政年份:
    2021
  • 资助金额:
    $ 17.31万
  • 项目类别:
Elucidation of novel anti-angiogenic therapies for the prevention and treatment of neovascular glaucoma
阐明预防和治疗新生血管性青光眼的新型抗血管生成疗法
  • 批准号:
    10706506
  • 财政年份:
    2021
  • 资助金额:
    $ 17.31万
  • 项目类别:
Project 3 - Brayboy
项目 3 - Brayboy
  • 批准号:
    9883807
  • 财政年份:
    2020
  • 资助金额:
    $ 17.31万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了